188 related articles for article (PubMed ID: 25315074)
21. Full-dose 90Y ibritumomab tiuxetan therapy is safe in patients with prior myeloablative chemotherapy.
Jacobs SA; Vidnovic N; Joyce J; McCook B; Torok F; Avril N
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7146s-7150s. PubMed ID: 16203814
[TBL] [Abstract][Full Text] [Related]
22. Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life.
Andrade-Campos MM; Montes-Limón AE; Soro-Alcubierre G; Grasa JM; Lopez-Gómez L; Baringo T; Giraldo P
Ann Hematol; 2014 Dec; 93(12):1985-92. PubMed ID: 24985089
[TBL] [Abstract][Full Text] [Related]
23. Use of 90Y-ibritumomab tiuxetan in non-Hodgkin's lymphoma.
Marcus R
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S36-43. PubMed ID: 15786024
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin).
Borghaei H; Schilder RJ
Semin Nucl Med; 2004 Jan; 34(1 Suppl 1):4-9. PubMed ID: 14762738
[TBL] [Abstract][Full Text] [Related]
25. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.
Emmanouilides C; Witzig TE; Gordon LI; Vo K; Wiseman GA; Flinn IW; Darif M; Schilder RJ; Molina A
Leuk Lymphoma; 2006 Apr; 47(4):629-36. PubMed ID: 16690521
[TBL] [Abstract][Full Text] [Related]
26. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.
Witzig TE; Flinn IW; Gordon LI; Emmanouilides C; Czuczman MS; Saleh MN; Cripe L; Wiseman G; Olejnik T; Multani PS; White CA
J Clin Oncol; 2002 Aug; 20(15):3262-9. PubMed ID: 12149300
[TBL] [Abstract][Full Text] [Related]
27. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
28. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
Wiseman GA; Witzig TE
Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
[TBL] [Abstract][Full Text] [Related]
29. B-cell non-Hodgkin lymphoma: PET/CT evaluation after 90Y-ibritumomab tiuxetan radioimmunotherapy--initial experience.
Ulaner GA; Colletti PM; Conti PS
Radiology; 2008 Mar; 246(3):895-902. PubMed ID: 18258810
[TBL] [Abstract][Full Text] [Related]
30. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
[TBL] [Abstract][Full Text] [Related]
31. Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome.
Zinzani PL; Gandolfi L; Stefoni V; Fanti S; Fina M; Pellegrini C; Montini GC; Derenzini E; Broccoli A; Argnani L; Pileri S; Baccarani M
Clin Lymphoma Myeloma Leuk; 2010 Aug; 10(4):258-61. PubMed ID: 20709661
[TBL] [Abstract][Full Text] [Related]
32. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.
Arnason JE; Luptakova K; Rosenblatt J; Tzachanis D; Avigan D; Zwicker JI; Levine J; Kim M; Parker JA; Grant B; Joyce RM
Acta Haematol; 2015; 133(4):347-53. PubMed ID: 25677780
[TBL] [Abstract][Full Text] [Related]
33. Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.
Illidge TM; Mayes S; Pettengell R; Bates AT; Bayne M; Radford JA; Ryder WD; Le Gouill S; Jardin F; Tipping J; Zivanovic M; Kraeber-Bodere F; Bardies M; Bodet-Milin C; Malek E; Huglo D; Morschhauser F
J Clin Oncol; 2014 Jan; 32(3):212-8. PubMed ID: 24297953
[TBL] [Abstract][Full Text] [Related]
34. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.
Morschhauser F; Dreyling M; Rohatiner A; Hagemeister F; Bischof Delaloye A
Oncologist; 2009; 14 Suppl 2():17-29. PubMed ID: 19819921
[TBL] [Abstract][Full Text] [Related]
35. 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years.
Rieger K; De Filippi R; Lindén O; Viardot A; Hess G; Lerch K; Neumeister P; Stroux A; Peuker CA; Pezzutto A; Pinto A; Keller U; Scholz CW
Ann Hematol; 2022 Apr; 101(4):781-788. PubMed ID: 35150296
[TBL] [Abstract][Full Text] [Related]
36. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.
Gordon LI; Molina A; Witzig T; Emmanouilides C; Raubtischek A; Darif M; Schilder RJ; Wiseman G; White CA
Blood; 2004 Jun; 103(12):4429-31. PubMed ID: 15016644
[TBL] [Abstract][Full Text] [Related]
37. Yttrium-90 ibritumomab tiuxetan radioimmunotherapy in Richter syndrome.
Tsimberidou AM; Murray JL; O'Brien S; Wierda WG; Keating MJ
Cancer; 2004 May; 100(10):2195-200. PubMed ID: 15139064
[TBL] [Abstract][Full Text] [Related]
38. [Radioimmunotherapy with (90)Y-Ibritumomab tiuxetan].
Brockmann H; Biersack HJ
Dtsch Med Wochenschr; 2006 Mar; 131(9):438-40. PubMed ID: 16493567
[No Abstract] [Full Text] [Related]
39. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice.
Jacene HA; Filice R; Kasecamp W; Wahl RL
J Nucl Med; 2007 Nov; 48(11):1767-76. PubMed ID: 17942813
[TBL] [Abstract][Full Text] [Related]
40. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial.
Cabrero M; Martin A; Briones J; Gayoso J; Jarque I; López J; Grande C; Heras I; Arranz R; Bernal T; Perez-Lopez E; López-Godino O; Conde E; Caballero D
Biol Blood Marrow Transplant; 2017 Jan; 23(1):53-59. PubMed ID: 27771496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
